Matinas BioPharma Holdings, Inc. filings document a clinical-stage biopharmaceutical issuer built around lipid nanocrystal delivery technology and MAT2203, its oral amphotericin B antifungal candidate. Regulatory disclosures include material-event reports, proxy matters, governance changes, capital-structure actions, and public-company compliance items.
Recent MTNB filings cover NYSE American continued-listing notices, board and officer changes, executive compensation arrangements, warrant exchanges, authorized-share amendments, stockholder meeting results, and equity incentive plan approvals. These records also disclose the company’s common-stock structure, voting matters, risk-related listing issues, and formal reporting obligations as a public biotechnology company.
Matinas BioPharma Holdings, Inc. (MTNB) effected a 1-for-15 reverse stock split at 12:01 a.m. Eastern Time on September 28, 2026: every 15 issued and outstanding common shares became one share. No fractional shares were issued; holders otherwise entitled to fractions are entitled to a proportional cash payment. The split did not change the common stock’s par value or authorized share count, and outstanding options, warrants and convertible preferred stock were adjusted under their terms. MTNB anticipated split-adjusted trading at the market open on September 28, subject to NYSE American approval.
Matinas BioPharma Holdings, Inc. (MTNB) has approved a 1-for-15 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on September 28, 2026, after which the shares are expected to trade on a split-adjusted basis under the existing symbol MTNB.
Each stockholder’s shares will be automatically converted by dividing their issued and outstanding shares by 15, with cash paid in lieu of fractional shares. The company states that ownership percentages, voting power, par value and authorized share counts will remain substantially unchanged, although it notes there can be no assurance the reverse split will enable it to maintain its NYSE American listing.
Matinas BioPharma Holdings, Inc. (MTNB) reported that on August 31, 2026 it received another notice from NYSE American that it is not in compliance with the continued listing standard requiring stockholders’ equity of at least $2.0 million when a company has recent operating or net losses. Matinas reported stockholders’ equity of $1.8 million as of June 30, 2026 and losses from continuing operations and/or net losses in its five most recent fiscal years.
The company was previously notified that it also fails the $4.0 million and $6.0 million stockholders’ equity standards under Sections 1003(a)(ii) and 1003(a)(iii). NYSE American has accepted Matinas’ remediation plan and granted a plan period through October 2, 2027. During this period the shares will continue trading on NYSE American and carry the .BC noncompliance indicator. The notice does not change day-to-day business operations or SEC reporting, but Matinas remains subject to potential delisting if it does not regain compliance.
Matinas BioPharma Holdings, Inc. (MTNB) is pursuing a business combination under a Business Combination Agreement with GH Power and a newly formed Ontario parent company expected to be named GH Power International, which is expected to close in the fourth quarter of 2026. GH Power is a Canadian critical minerals and clean energy technology company whose reactor converts aluminum and water into fuel-cell-grade hydrogen, high-purity aluminum oxide, and thermal energy, supported by a pilot facility in Hamilton, Ontario and partnerships with Canadian research institutions. Future public disclosures, including a planned Form F-4 registration statement with a proxy statement/prospectus, are expected to detail GH Power’s commercial pipeline and the combined company’s capitalization. Closing is subject to multiple conditions, including shareholder and court approvals, NYSE American listing, GHP International qualifying as a foreign private issuer, and completion of GH Power financing with gross proceeds of at least $15.0 million. The communication is sponsored content; Matinas pays Wall Street Wire $6,500 per month for coverage.
Matinas BioPharma Holdings, Inc. reported a net loss of $1,326 thousand for the quarter and $3,247 thousand for the six months ended June 30, 2026, narrowing losses from 2025. Total assets were $3,412 thousand, including $761 thousand of cash and cash equivalents and stockholders’ equity of $1,800 thousand.
The company continues to incur operating losses and states that existing cash is not sufficient to fund operations for 12 months, concluding that substantial doubt exists about its ability to continue as a going concern. It used $3,437 thousand of cash in operating activities in the first half of 2026.
Matinas agreed to a Business Combination with GH Power Inc., under which current Matinas equityholders are expected to own about 9% of the combined Pubco, and to sell its Nanotechnologies subsidiary (owner of MAT2203) to Azurity for up to $21,500 thousand plus royalties. It also raised $575 thousand via Series D preferred stock and $2,323 thousand through a warrant inducement. Completion of the Business Combination and Stock Sale is subject to multiple conditions and is not assured.
Matinas BioPharma investor Adam K. Stern updated his ownership in the company’s common stock. Sanitam Partners LLC now reports 0 shares, while Stern reports 2,972,524 shares beneficially owned, representing 9.99% of the common stock based on 13,692,796 shares outstanding. This stake includes common shares, warrants and preferred stock held across several Stern-related entities, all subject to 4.99% and 9.99% beneficial ownership limitations. Due to the voting rights of the preferred stock, Stern may vote the equivalent of 13.1% of the outstanding common stock. The amendment also describes July 2026 inducement transactions in which Stern-related entities exercised existing warrants at $0.35 per share for cash and received equal amounts of new unregistered warrants, exercisable for five years once stockholder approval for the underlying shares is obtained.
Matinas BioPharma Holdings, Inc. reporting person Adam K. Stern, a greater-than-10% owner, reported a series of warrant and preferred stock transactions mainly involving exercises and restructurings through affiliated entities. On July 10, 2026, entities associated with Stern exercised for cash a total of 1,067,145 warrants at $0.35 per share to acquire the same number of common shares, pursuant to inducement offer letter agreements under which the company agreed to issue new unregistered common stock purchase warrants in a private placement, exercisable only after Inducement Stockholder Approval. Stern also received 141,462 solicitation agent warrants as part of a distribution from ThinkEquity LLC. Earlier, on October 16, 2025, an affiliated plan received 800,000 warrants and 265 shares of Series C Convertible Preferred Stock in connection with a settlement agreement, and a related distribution from Sanitam Partners LLC shifted preferred stock and warrants to A.K.S. Family Partners LP. A remaining indirect position in Series C Convertible Preferred Stock is reported, convertible into 172,354 common shares.
Sanitam Partners LLC, a more than ten percent owner of Matinas BioPharma Holdings, Inc., reported restructuring transactions dated June 10, 2026. It disposed of Series C Convertible Preferred Stock and warrants through a distribution of its holdings to its members. Following these transactions, Sanitam no longer beneficially owns any securities of Matinas BioPharma.
Matinas BioPharma Holdings, Inc. and GH Power Inc. have entered into a definitive Business Combination Agreement under which a newly formed Ontario corporation, expected to be named GH Power International Inc., will become the public parent of both companies. If completed, existing GH Power shareholders are expected to own approximately 91% of GH Power International’s outstanding equity at closing and existing Matinas stockholders about 9%, subject to adjustment under the transaction documents.
The combined company’s common shares are expected to list on the NYSE American, contingent on approval of the listing application and satisfaction of applicable standards. Closing is targeted for the fourth quarter of 2026 and is conditioned on shareholder and securityholder approvals, effectiveness of a Form F-4 registration statement, various court and regulatory approvals, and GH Power completing financing that generates at least $15.0 million in gross proceeds. After completion, GH Power International is expected to focus on commercializing GH Power’s modular reactor technology, which is designed to convert scrap metals and water into clean hydrogen, usable thermal energy, and high-purity alumina.
Matinas BioPharma Holdings, Inc. and GH Power Inc. highlight GH Power’s ongoing collaboration discussions with TKMS after TKMS was selected as preferred supplier for Canada’s Patrol Submarine Project. GH Power may participate in Industrial and Technological Benefits initiatives, which could provide non-dilutive funding, but any role remains subject to Canadian government project selection and definitive agreements with TKMS.
The communication also describes a definitive Business Combination Agreement under which GH Power would become a wholly owned subsidiary of a new Ontario company expected to be named GH Power International. Existing GH Power shareholders are expected to own approximately 91% of GH Power International’s outstanding equity at closing. GH Power International’s shares are expected to list on the NYSE American, and completion of the transaction depends on multiple closing conditions, including shareholder, court, regulatory and exchange approvals and GH Power financing resulting in gross proceeds of at least $15.0 million.